Protein Kinase Inhibitors: all 15,147 studies that test it

Page 35 of 152. Open to participants first (2,533), then studies with results posted, then the rest; newest registration first within each.

• Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT03702725Phase 1Results posted
• Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03698994Phase 2Results posted
• Topical Ruxolitinib Lichen PlanusCompletedNCT03697460Phase 2Results posted
• Itacitinib + Everolimus in Hodgkin LymphomaActive, not recruitingNCT03697408Phase 1/2Results posted
• A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) StudyTerminatedNCT03693625Phase 2Results posted
• Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal CancerCompletedNCT03693170Phase 2Results posted
• Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone MetastasisCompletedNCT03691493Phase 2Results posted
• A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyActive, not recruitingNCT03690388Phase 3Results posted
• An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate CancerTerminatedNCT03690141Phase 2Results posted
• Ibrutinib Plus Rituximab for cGVHD Following Allo-SCTTerminatedNCT03689894Phase 1/2Results posted
• Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell LymphomaTerminatedNCT03684694Phase 1/2Results posted
• Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand EczemaCompletedNCT03683719Phase 2Results posted
• A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid ArthritisCompletedNCT03682705Phase 2Results posted
• Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell CarcinomaCompletedNCT03680521Phase 2Results posted
• Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's MacroglobulinemiaTerminatedNCT03679624Phase 2Results posted
• A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)CompletedNCT03675581Phase 1Results posted
• A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.CompletedNCT03675477Phase 2Results posted
• A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With ImatinibActive, not recruitingNCT03673501Phase 3Results posted
• Ribociclib and Letrozole Treatment in Ovarian CancerActive, not recruitingNCT03673124Phase 2Results posted
• Long Term Safety Observation of Crizotinib in Chinese NSCLC PopulationTerminatedNCT03672643Phase 4Results posted
• Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.CompletedNCT03671330Phase 2Results posted
• A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic SystemTerminatedNCT03670030Phase 2Results posted
• A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT03666143Phase 1Results posted
• Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue SarcomasTerminatedNCT03660930Phase 1/2Results posted
• Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneActive, not recruitingNCT03660826Phase 2Results posted
• A Renal Impairment Study for PF-04965842CompletedNCT03660241Phase 1Results posted
• Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal CancerActive, not recruitingNCT03657641Phase 1/2Results posted
• A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic CholangiocarcinomaTerminatedNCT03656536Phase 3Results posted
• Effect of Copanlisib on Metformin Pharmacokinetics and PharmacodynamicsCompletedNCT03655301Phase 1Results posted
• PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706TerminatedNCT03655236Phase 2Results posted
• Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedNCT03654833Phase 2Results posted
• Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid LeukemiaActive, not recruitingNCT03654768Phase 2Results posted
• Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic DermatitisTerminatedNCT03654755Phase 2Results posted
• Liver Transplantation With Tregs at UCSFTerminatedNCT03654040Phase 1/2Results posted
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT03653026Phase 3Results posted
• Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung CancerCompletedNCT03647488Phase 2Results posted
• To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)CompletedNCT03644186Phase 2Results posted
• Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial CancerCompletedNCT03643510Phase 2Results posted
• M6620 Plus Standard Treatment in Oesophageal and Other CancerCompletedNCT03641547Phase 1Results posted
• Sunitinib in Sarcomas of the Central Nervous SystemTerminatedNCT03641326Phase 2Results posted
• Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction CancerCompletedNCT03641313Phase 2Results posted
• Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic TherapyTerminatedNCT03640481Phase 2Results posted
• Efficacy and Safety of TD-1473 in Crohn's DiseaseTerminatedNCT03635112Phase 2Results posted
• Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast CancerCompletedNCT03633331Phase 2Results posted
• Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid CancerTerminatedNCT03630120Phase 2Results posted
• Effect of Tepotinib on PK of CYP3A Substrate MidazolamCompletedNCT03628339Phase 1Results posted
• Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring SubjectsCompletedNCT03627767Phase 3Results posted
• A Study of INCB050465 in Primary Sjögren's SyndromeCompletedNCT03627065Phase 2Results posted
• A Hepatic Impairment Study for PF-04965842.CompletedNCT03626415Phase 1Results posted
• A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System MetastasesCompletedNCT03625141Phase 2Results posted
• Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With PsoriasisCompletedNCT03624127Phase 3Results posted
• Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell LymphomaCompletedNCT03623373Phase 2Results posted
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)CompletedNCT03616964Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus ErythematosusTerminatedNCT03616912Phase 3Results posted
• Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic GlucocorticoidsCompletedNCT03616184Phase 2Results posted
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT03611751Phase 3Results posted
• Lenvatinib and Pembrolizumab Simultaneous Combination StudyCompletedNCT03609359Phase 2Results posted
• A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaCompletedNCT03607487Phase 2Results posted
• A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)CompletedNCT03607422Phase 3Results posted
• Ursodeoxycholic Acid (UDCA) for Hepatic SarcoidosisTerminatedNCT03602976Phase 2Results posted
• A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid TumorsTerminatedNCT03601897Phase 1/2Results posted
• Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal CancerTerminatedNCT03601507Phase 2Results posted
• Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung CancerActive, not recruitingNCT03600701Phase 2Results posted
• An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's DiseaseTerminatedNCT03599622Phase 2Results posted
• DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerTerminatedNCT03599518Phase 1Results posted
• Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS TumorsActive, not recruitingNCT03598244Phase 1Results posted
• A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung CancerCompletedNCT03596866Phase 3Results posted
• A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)Active, not recruitingNCT03595124Phase 2Results posted
• Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal CancerTerminatedNCT03592641Phase 2Results posted
• A Futility Trial of Sirolimus in Multiple System AtrophyTerminatedNCT03589976Phase 2Results posted
• A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic LeukemiaActive, not recruitingNCT03589326Phase 3Results posted
• A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular CarcinomaCompletedNCT03586973Phase 2Results posted
• A Study of ATI-502 Topical Solution for the Treatment of Atopic DermatitisCompletedNCT03585296Phase 2Results posted
• GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseTerminatedNCT03584516Phase 2/3Results posted
• Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic TumorsCompletedNCT03583086Phase 1/2Results posted
• Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung CancerCompletedNCT03581487Phase 1/2Results posted
• Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLLActive, not recruitingNCT03580928Phase 2Results posted
• (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic MastocytosisCompletedNCT03580655Phase 2Results posted
• Tofacitinib for Inflammatory Eye DiseaseStatus unknownNCT03580343Phase 2Results posted
• Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.CompletedNCT03578367Phase 2Results posted
• Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous LeukemiaTerminatedNCT03576547Phase 1/2Results posted
• Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic DermatitisCompletedNCT03575871Phase 3Results posted
• Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLLTerminatedNCT03572634Phase 1/2Results posted
• A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia AreataCompletedNCT03570749Phase 2/3Results posted
• A Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaCompletedNCT03569371Phase 2Results posted
• Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)CompletedNCT03569293Phase 3Results posted
• CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast CancerActive, not recruitingNCT03568422Phase 1/2Results posted
• A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisActive, not recruitingNCT03568318Phase 3Results posted
• Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast CancerTerminatedNCT03566485Phase 1/2Results posted
• A Study of ZN-c5 in Subjects With Breast CancerCompletedNCT03560531Phase 1/2Results posted
• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic DermatitisTerminatedNCT03559270Phase 3Results posted
• JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT03557970Phase 2Results posted
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)TerminatedNCT03555149Phase 1/2Results posted
• Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III MelanomaCompletedNCT03554083Phase 2Results posted
• Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)TerminatedNCT03552029Phase 1Results posted
• Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia AreataCompletedNCT03551821Phase 2Results posted
• Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related OutcomesCompletedNCT03551626Phase 3Results posted
• Tepotinib Hepatic Impairment TrialCompletedNCT03546608Phase 1Results posted
• Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal CancerCompletedNCT03542877Phase 2Results posted
• Lorlatinib Renal Impairment StudyCompletedNCT03542305Phase 1Results posted

← Protein Kinase Inhibitors overview